A securities class action has been filed against REGENXBIO Inc., alleging the company disseminated materially false and misleading statements regarding its RGX-111 gene therapy program and related clinical trial outcomes. The litigation, initiated by law firm Bronstein, Gewirtz & Grossman LLC, encompasses investors who acquired REGENXBIO securities during the period spanning February 9, 2022 through January 27, 2026.
According to the complaint, shareholders contend they sustained losses due to alleged misrepresentations and omissions concerning the development and efficacy profile of the company's lead therapeutic candidate. The case seeks to recover damages for affected investors during the specified timeframe, with the court establishing April 14, 2026 as the deadline for investors to be designated as lead plaintiff in the proceedings.
Investors who held REGENXBIO stock during the class period and believe they were harmed by the alleged disclosures are encouraged to contact the law firm to discuss potential participation in the action. The outcome of this litigation could have material implications for the company's valuation and shareholder relationships.